Sharciga & Xeerar
bcbs-gender-affirming-policy-doc-require-highlighted.pdf
Natiijooyinka Raadinta
Soo bandhiga 1231 - 1240 ee natiijooyinka 4162
Sharciga & Xeerar
bcbs-gender-affirming-policy-hrt-language-highlighted.pdf
Bixiye
QP88-22 Provider Press: Q2 2022
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022
Bixiye
QP89-22 Provider Press: Q3 2022
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022
Bixiye
QP87-22 MHCP Pharmacy Benefit Update: New drug-related Prior Authorization (PA) Criteria: Strensiq® (asfotase alfa)
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022
Bixiye
QP86-22 MHCP Pharmacy Benefit Update: New drug-related Prior Authorization (PA) Criteria: Vtama® (tapinarof)
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022
Bixiye
QP84-22 MHCP Pharmacy Benefit Update: New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Camzyos™ (mavacamten)
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022
Bixiye
QP85-22 MHCP Pharmacy Benefit Update: New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Radicava® (edaravone)
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022
Bixiye
QP83-22 MHCP Pharmacy Benefit Exclusion for Somatuline® Depot and Sandostatin® LAR Depot
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022
Bixiye
P58-20 Hereditary Angioedema (HAE) Drug Prior Authorization Management Changes for generic Icatibant, Firazyr, Haegarda, and Takhzyro — Effective October 5, 2020
Taariikhda barnaamijka Dhaqangalayso Agosto 03, 2020